ID   Mela15
AC   CVCL_VN58
SY   MELA15
DR   ABM; T8319
DR   cancercelllines; CVCL_VN58
DR   Wikidata; Q95988714
RX   DOI=10.1158/1538-7445.AM2015-2417;
RX   PubMed=29416592;
CC   Doubling time: 30 hours (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (Direct_author_submission).
CC   Miscellaneous: Cell line information from personal communication of Marlow, Laura A.
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 10
ST   D18S51: 15
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 13,14
ST   FGA: 20
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 10
//
RX   DOI=10.1158/1538-7445.AM2015-2417;
RA   Harris A.L., Marlow L.A., Mathias A.C., Dawson L.K., Durham W.F.,
RA   Meshaw K.A., Mullin R.J., Small D.L., Synnott A., Wu K., Milosevic D.,
RA   Netzel B.C., Grebe S.K.G., Markovic S.N., Copland J.A. 3rd;
RT   "Characterization of novel patient derived melanoma xenografts and
RT   cell lines in response to targeted therapies.";
RL   Cancer Res. 75 Suppl. 15:2417-2417(2015).
//
RX   PubMed=29416592; DOI=10.18632/oncotarget.21545; PMCID=PMC5787466;
RA   von Roemeling C.A., Caulfield T.R., Marlow L.A., Bok I., Wen J.,
RA   Miller J.L., Hughes R., Hazlehurst L.A., Pinkerton A.B., Radisky D.C.,
RA   Tun H.W., Kim Y.S.B., Lane A.L., Copland J.A. 3rd;
RT   "Accelerated bottom-up drug design platform enables the discovery of
RT   novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.";
RL   Oncotarget 9:3-20(2018).
//